Making the compound Amanitin available for cancer therapies

Our focus is on oncology and our mission is to research and develop drugs for cancer patients enabling them to receive a targeted and tailor-made course of treatment that is both highly effective and as well-tolerated as possible.

ADC Drug Development

As a drug development company we concentrate on combining the targeting properties of antibodies with the effectiveness of an ultra-potent toxin with antibody-drug conjugates (ADC), that are more effective against cancer. 

Key USP of our technology is the potential to treat multi-resistant tumors and "dormant or quiescent" tumor cells, which are regarded as a main reason for metastasis and resistance.

Read more

Latest Releases

Latest News

  • 08.01.2018
    PR: Heidelberg Pharma AG and Advanced Proteome Therapeutics Progress Collaborative Program
  • 21.11.2017
    Heidelberg Pharma AG raises approximately EUR 34.4 million from capital measure      
  • 16.11.2017
    Heidelberg Pharma AG announces subscription price for new shares and conversion price for convertible bonds from ongoing capital measure
  • 13.11.2017
    Heidelberg Pharma AG announces results from research collaboration with Heidelberg University and the DKFZ to be presented at ASH Annual Meeting
  • More Press Releases
By Master en comunicación


As a preclinical CRO we offer explorative pharmacology, drug metabolism and pharmacokinetics (DMPK) analysis and molecular biology.

Our core competence is the preclinical profiling of small molecules or biologicals destined for the treatment of cancer or inflammatory/autoimmune diseases.

Read More

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.